Guide
Retatrutide: is what you bought real?
No approved retatrutide product exists anywhere in the world. Eli Lilly is still testing it and plans to apply for approval in the first quarter of 2027. Every vial or pen sold as retatrutide today is unapproved.
Why "looks real" means nothing here
With Ozempic or Mounjaro you can compare a pen against the genuine product. With retatrutide there is no genuine product to compare against. Packaging, logos and "pharmaceutical grade" labels are all made up by the seller. Only an analytical test can show whether the vial contains retatrutide at all.
What regulators and researchers have found
| Date | Finding | Source |
|---|---|---|
| Aug 2026 | Eli Lilly filed six lawsuits against med spas and vendors and referred thousands of sellers to regulators. Dozens of sellers offer retatrutide at up to $600. | Axios |
| Jun 2026 | At least 14 hospitalisations linked to retatrutide reported to the FDA. Of 14 companies sent FDA warning letters since 2024, 8 were still selling it in May 2026. | Public Citizen |
| Oct 2025 | A UK factory raid found about 2,000 pens labelled tirzepatide or retatrutide and tens of thousands of empty pens. | The Standard / MHRA |
What we don't cover
We don't give dosing information or say where to buy retatrutide. If you are considering it, talk to a doctor about approved options first.
Checking identity
Several labs test specifically for retatrutide, at $250–400 per sample. See testing options.